Diagnostics company Sekisui Diagnostics revealed on Tuesday that the Acucy Influenza A&B Test Class II assay has passed the US Food and Drug Administration's (FDA) 510(k) clearance as well as the CLIA Waiver for use on the Acucy Reader in either the point-of-care or laboratory setting to help improve patient outcomes, maximize clinical efficiencies and reduce operational budgets.
The company added that the Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. The Influenza A&B Test combined with the Reader provides clinicians with standardized and definitive result interpretation.
Upon clearance, the Acucy Influenza A&B test expands the company's flu portfolio to include all three commonly used modalities in the CLIA ((Clinical Laboratory Improvement Amendments)) Waived environment: OSOM Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the Silaris Influenza A&B Test (molecular point-of-care).
Since the launch of rapid molecular tests and the 2018 FDA Flu reclassification focusing on the improved performance of on market rapid immunoassays, the clinicians are now more confident in test results and therefore better able to provide direct therapy, said the company.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress